tbuckley/cabot-search huggingface dataset:
Neoadjuvant therapy and rates of margin re-excision in patients with invasive breast cancer.
Authors: E. M. Hanna, S. Musunuru, T. Flippo-Morton, T. Sarantou, H. J. Norton, M. Calhoun, R. L. White
Journal: Journal of Clinical Oncology (2011)

131 Background: Many patients with invasive breast cancer receive neoadjuvant chemotherapy (NACT) prior to undergoing definitive surgical management in an effort to facilitate breast conservation. This study compares the re-excision rates of patients undergoing NACT with those who proceed directly to surgical treatment. A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between November 2007 and June 2010 was performed. Re-excision rates were calculated for patients who received NACT and were then compared to a group of contemporaneous patients who did not receive neoadjuvant treatment (non-NACT). Re-excisions were routinely performed for disease &lt;2mm from the margin. Patients with DCIS or LCIS were excluded. For statistical analysis, t-test and chi square tests were performed using SAS v9.2. Results: During the study period, 152 patients received neoadjuvant chemotherapy and then underwent surgical treatment of breast cancer. Of these patients, 108 (71.0%) underwent partial mastectomy as primary treatment, 44 (29.0%) underwent mastectomy. As a comparison group, we evaluated 188 consecutive patients diagnosed with invasive breast cancer who underwent initial treatment in the form of partial mastectomy. Table 1 demonstrates the characteristics of NACT and non-NACT patients and margin re-excision rates. Conclusions: Neoadjuvant chemotherapy is often administered in an effort to allow women with larger tumors to pursue breast conservation therapy. This study demonstrates that the rate of margin re-excision in NACT patients is not statistically different from those patients who undergo partial mastectomy as their primary treatment. [Table: see text]
Extensive Chronic Graft-Versus-Host-Disease Significantly Increases the Risk of Severe and Multifocal Genital Tract HPV Disease in Long-Term Survivors of Allogeneic Stem Cell Transplantation
Authors: Dana L Shanis, Prathima Anandi, Caitlin Grant, Priyanka A Pophali, Eleftheria Koklanaris, Bipin N. Savani, Austin John Barrett, Minoo Battiwalla, Pamela Stratton
Journal: Blood (2015)
No Mutations in the RPL11 Gene Detected in Greek Patients with Diamond Blackfan Anemia
Authors: Antonis Kattamis, Polyxeni Delaporta, Christalena Sofocleous, Maria Kalmanti, Sophia Polychronopoulou, Evagelia Lagona, Marina Economou, Lydia Kossiva, Stavroula Kostaridou
Journal: Blood (2011)
Prophylactic Nrf2 Activation Halts Progression of the Severe Adult Phenotype of Sickle Cell Disease in Transgenic Mice
Authors: Samit Ghosh, Chibueze A. Ihunnah, Rimi Hazra, Amma T. Owusu-Ansah, Jason M Hansen, David R. Archer, Solomon Fiifi Ofori-Acquah
Journal: Blood (2015)
Using Gleason pattern 5 to refine risk stratification for prostate cancer patients treated with dose-escalated radiotherapy and androgen-deprivation therapy.
Authors: A. Sabolch, F. Y. Feng, S. Daignault-Newton, S. Halverson, K. Blas, L. Phelps, K. B. Olson, H. M. Sandler, D. A. Hamstra
Journal: Journal of Clinical Oncology (2011)

15 Background: The division of Gleason score (GS) into three categories (2-6, 7, 8-10), may not fully utilize its prognostic power as shown by recent reports demonstrating that the presence of Gleason Pattern 5 (GP5) is a strong adverse prognostic factor. Therefore, we analyzed clinical outcomes for patients treated with dose-escalated radiation therapy (RT) based upon the presence or absence of GP5 within the biopsy specimens. Methods: Clinical outcomes were analyzed for 718 men treated for localized prostate cancer with definitive external beam RT to at least 75 Gy. We assessed the impact of GP5 as well as pre-treatment and treatment related factors on freedom from biochemical failure (FFBF), freedom from metastasis (FFM), cause-specific survival (CSS), and overall survival (OS). Results: Median follow-up was 64 months. At biopsy, 89% of patients had no GP5 while 11% had GP5. There was no difference in age, co-morbid illness, clinical T-stage, PSA, or the use or duration of androgen deprivation therapy (ADT) between GS8 without GP5 and GS8-10 with GP5. The presence of GP5 predicted lower FFM (p&lt;0.002 [HR: 3.4{1.7-7.1}]), CSS (p&lt;0.0001 [HR: 12.9 {5.4-31}]), and OS (p&lt;0.0001 [HR: 3.6 {2.0-6.5}]) when compared to GS8 (without GP5). Ten-year FFM, CSS, and OS were 89%, 98%, and 57% for those with Gleason 8 prostate cancer without GP5 as compared to 61%, 55%, and 31% for those with GP5. In addition, both FFM and CSS were strongly influenced by ADT use concurrent with RT. On multivariate analysis GP5 was the strongest prognostic factor for all clinical end-points. Conclusions: The presence of GP5 predicts for worse clinical behavior, which therefore needs to be accounted for by risk stratification schemes. Further intensification of local and/or systemic therapy may be appropriate for such patients. No significant financial relationships to disclose.
The future of NHS dentistry in Scotland
Authors: C Albert Yeung
Journal: BMJ (2016)

Appleby examined the link between deprivation and use of dental services in England, Wales, and Northern Ireland.1 Scotland, because it has devolved responsibility for the NHS, decided not to participate in the adult dental health survey 2009 and the children’s dental health survey 2013.

Recent figures from the national dental inspection programme in Scotland show some …
Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),
Authors: Nelly G. Adel, Elaine Duck, Karen Collum, Emily Mccullagh, Lilian Reich, Heather Landau, Sergio Giralt, Hani Hassoun
Journal: Blood (2011)
Triple-negative breast cancer: The effect of guideline-adherent adjuvant treatment on the cumulative survival—A retrospective multicenter cohort study of 3,658 patients.
Authors: L. Schwentner, R. Wolters, M. Wischnewsky, R. Kreienberg, A. Wöckel
Journal: Journal of Clinical Oncology (2011)

1063 Background: Triple negative breast cancer (TNBC) constitutes an aggressive subtype in breast cancer accompanied with a significant decrease in overall survival (OAS) and disease free survival (RFS). This retrospective cohort study investigates the following queries: (1) Is there an impact of guideline adherent treatment on RFS and OAS in TNBC? (2) Which adjuvant treatment has the most important impact on RFS and OAS in TNBC? Methods: This German multi-center [16 participating hospitals all are certified as breast centers] retrospective cohort study included 3658 patients from 2000 until 2005. The definition of guideline adherence was based on the German national S3 guideline (2004). Results: 371(10.1%) were TNBC [median age(years): 60(range 28-97)]. 13.8% premenopausal/ 9.3% postmenopausal of the patients were TNBC. 90.3% of TNBC-patients were intermediate-/high-risk (Nottingham-prognostic index) and 76.5% were GIII. Compared to HR-pos./HER2-neg.-BC as reference, RFS of TNBC was significantly worse (HR=2.86; 95%CI: 2.17-3.76; p<0.001). Furthermore 5 years RFS (OAS) is significantly lower in TNBC vs. non-TNBC [RFS: 74,8% (95%CI:68.8%-80.8%) vs. 86.5%(95%CI:84.6%-88,4%); logrank p<0.001)] (OAS:75.8%(95%CI:69.9%-81.8%) vs. 86.0%(95%CI:84.1%-87.9%); logrank p<0.001)]. The most important parameters predicting RFS or OAS in TNBC are nodal status, grading, guideline adherent surgery, radiotherapy and chemotherapy. Overall 66.9% TNBC had one or more guideline violations, which subsequently impaired RFS and OAS (Ranking of guideline violations with respect to RFS: Radiotherapy (HR=2.92;95%CI(2.24-3.81); p<0.001), chemotherapy(HR=2.16;95%CI(1.70-2.74); p<0.001), initial surgical intervention(HR=2.03;95%CI(1.36-3.04); p=0.001) and lymph node dissection(HR=1.54;95%CI(1.05-2.25); p=0.027). Conclusions: Patients with TNBC have primarily a worse prognosis in terms of RFS and OAS than patients with primarily non-TNBC phenotype. There is a strong association between guideline adherence and RFS/OAS of patients with TNBC. The outcome decreases significantly with the number of guideline violations.
Mesenchymal stem cells can be specifically transplanted into the femur: a Magic result by Magnetism-induced cell target transplantation (MagiC-TT) in dual transgenic mice model
Authors: Qianli Jiang, Hao Huang, Qiusui Mai, Jia peng Wang, Yuncong Lu, Li Liu, Yifang Yuan, Peiran Zhao, Lezhong Yuan, Yanyan Ye, Yongjun Zhou, Jing Sun
Journal: Blood (2014)
Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype
Authors: Marcos R Estecio, Sirisha Maddipoti, Courtney D. DiNardo, Hui Yang, William S Stevenson, Carlos E. Bueso-Ramos, Sherry R. Pierce, Yue Wei, Guillermo Garcia-Manero
Journal: Blood (2014)
Determining the rate of tumor growth and decay in patients with metastatic breast cancer as an early efficacy endpoint: A study assessing ixabepilone efficacy.
Authors: L. Amiri-Kordestani, I. Jawed, J. Wilkerson, W. D. Stein, S. E. Bates, S. M. Swain, A. T. Fojo
Journal: Journal of Clinical Oncology (2011)

246 Background: Early efficacy assessment in drug development should help find new cancer therapies. We have developed a novel method to analyze tumor response to therapy by quantifying the rate of tumor regression (d) and growth (g). We have shown g is slower when pts are on effective therapy and that g correlates with survival (Stein et al, Oncologist 2008). We utilized this method to evaluate a phase III trial of capecitabine (CAP) ± IXA in second line therapy (Tomas et al, JCO 2007) and a three-cohort phase II trial in second and subsequent lines of therapy in pts with MBC consisting of (1) Daily X 5 IXA given to taxane (TAX)-naïve patients (Denduluri et al, JCO 2007); (2) Daily X 5 IXA in pts previously treated with TAX (Low et al, JCO 2005); and (3) Daily X 3 IXA in pts previously treated with TAX (Denduluri et al, Invest New Drug 2007). Methods: Using tumor measurements assessed by RECIST and a two-phase mathematical equation we determined d and g. Results: In the phase III study g was superior to PFS identifying a significant difference between the arms very early—before the 200th pt had enrolled. In an individual patient the g values could be estimated as early as the 3 rd evaluation, long before tumor growth was observed clinically. IXA + CAP in second line (g = 0.0018) was more effective than CAP (g = 0.0023) at reducing g, and more effective (p=0.0085) than single agent IXA in the Phase II study (g = 0.0027). Single agent IXA was comparably effective (p=0.814) in reducing the g of tumors previously exposed to a TAX (g = 0.0032) as in reducing the g of TAX-naïve tumors (g = 0.0035), consistent with its development as an agent active in TAX-refractory disease. Unlike differences in g, the d of single agent IXA (0.118) was comparable to that of IXA+CAP (0.0074) suggesting differences were primarily driven by effect on the growth of residual tumor. Conclusions: Unlike PFS, an incremental measure of efficacy, g is a continuous variable and can more accurately assess differences between treatments. Because calculations of g are indifferent to assessment intervals, estimating a tumor’s g allows comparison of efficacy across trials.
Accelerated partial breast brachytherapy after lumpectomy as salvage treatment for local recurrences after conservative treatment of breast cancer: Eighteen-year results of a nonrandomized comparison with mastectomy.
Authors: B. Guix, J. A. Lejarcegui, J. I. Tello, I. Guix, G. Zanon, L. Quinzaños, P. Palombo, J. M. Del-Campo, G. Galdon, M. Espino, A. Milla
Journal: Journal of Clinical Oncology (2011)

109 Background: To report the long-term results in a prospective group of patients (pts) treated for local recurrence after conservative treatment of breast cancer by a second conservative surgery or by total mastectomy. Methods: Between 12/1990 and 10/2004, 85 pts with &lt;3 cm, low-risk local recurrence after conservative treatment for breast cancer were offered total mastectomy. 48 of them refused it and were treated by a second lumpectomy followed by HDR brachytherapy implant to the tumor bed+margin. 30 Gy in 12 fractions in 5 days were given. Pts treated by mastectomy had no further radiotherapy. Postmenopausal pts with negative receptors had no systemic tx. The rest of the pts had chemo or hormones. No pts were lost for follow-up. Results: All pts completed treatment. During the 17-year, 1-year minimum follow-up, in the second conservative group there were 8 pts who had regional (2 pts) or distant metastases (6 pts) as their first site of failure. Three of them experienced a differed local recurrence and 1 died from the disease. In the total mastectomy group, there were 2 local recurrences, 1 regional recurrence, and 5 distant metastases as first site of failure. One patient died from the disease. Actuarial results at 17-year for second conservative and total mastectomy were respectively: local control 84.2%-71.7%; disease free survival 65.4%-63.8%; and survival 90.7% and 88.2%. Cosmetic results were satisfactory in 89.4% treated conservatively. No patient experienced arm edema or grade 3-4 early or late complications. Between the 14 pts that were followed-up for at least 10-years, 13 of them were with their breast still in place. Conclusions: Second conservative treatment by HDR brachytherapy was a safe and effective method of treatment for small-size, low-risk, local recurrence after local excision in conservatively treated pts. APBI with wide margins probed to be enough treatment, without significant side-effects in previously intesively irradiated patients. Lumpectomy and partial breast brachytherapy can be conidered the treatment of choice in selected patients with low-risk recurrent breast tumors.
STAT5 Phosphorylation Status by Flow Cytometry Is a Rapid and Reliable Tool for Diagnosis and Follow-up of Juvenile Myelomonocytic Leukemia
Authors: Giuseppe Gaipa, Cristina Bugarin, Marco Giordan, Silvia Bresolin, Daisuke Hasegawa, Marco Zecca, Daniela Longoni, Simone Menna, Giuseppe Basso, Geertruy te Kronnie, Andrea Biondi
Journal: Blood (2010)
A phase II trial evaluating efficacy of neo-/adjuvant EIA CTX, surgery, and radiation therapy in high-risk soft tissue sarcoma.
Authors: T. Schmitt, B. Kasper, M. Bischof, B. Lehner, S. Dietrich, A. Dimitrakopoulou-Strauss, L. G. Strauss, G. Mechtersheimer, P. Wuchter, A. D. Ho, G. Egerer
Journal: Journal of Clinical Oncology (2011)

10076 Background: Despite achieving adequate local control with surgery and irradiation (RTX), distant metastasis is a frequent event in high-risk soft tissue sarcoma (STS). Outcome for this population is dismal. Neo-/adjuvant chemotherapy (nCTX, aCTX) has been applied to eradicate micrometastases and facilitate definite surgery. Here we report on the results of our non-randomized, phase II, NeoWTS trial (EudraCT 2004-002501-72). Methods: Patients with high-risk STS (size >5cm, deep/extracompart. localization, tumor grades II-III) were included. The protocol comprised 4 cycles of nCTX (EIA, etoposide 125 mg/m2 iv day 1 and 4, ifosfamide 1500 mg/m2 iv days 1–4, doxorubicin 50 mg/m2 day 1, pegfilgrastim 6 mg sc day 5), definitive surgery with intraoperative RTX, aRTX and 4 adjuvant cycles of EIA. MRI scans were performed every 2 cycles and assessed according to RECIST criteria. Tumorregression was graded according to Salzer-Kuntschik. Results: Between 06/2005 and 03/2010 a total of 50 subjects (male=33, female=17, median age 50.1 years) were enrolled. STS were located in the upper extremity (n=4), lower extremity (n=31), trunk (n=11) and other loc. (n=4). Histological subtypes included liposarcoma (n=12), synovial sarcoma (n=9), NOS (n=9), MFH (n=8), leiomyosarcoma (n=5), and others (n=7) with tumor grades being II (n=21) and III (n=29). Response by RECIST criteria to nCTX was NED (n=3), PR (n=12), SD (n=31) and PD (n=4). Surgical status after nCTX was R0 (n=37), R1 (n=6) and R2 (n=2). Five patients did not undergo definitive surgery. Median follow-up was 30.5 months. Local recurrence occurred in 6 subjects. Distant metastasis was observed in 14 patients. Overall survival (OS) and disease-free survival (DFS) at 2 years was 83% and 63%, respectively. Median OS and DFS were not yet reached. Multivariant analysis failed to prove influence of resection status or grade of histological necrosis on OS or DFS. Severe toxicities included neutropenic fever (4/50), cardiac toxicity (2/50), and CNS toxicity (2/50) leading to CTX dose reductions in 4 subjects. Conclusions: The current protocol is feasible achieving local control rates, OS and DFS comparable to historical data on neo-/adjuvant CTX.
Methylation of the Proximal, Distal and Core Promoter of CEBPA in 574 Cases with Normal Karyotype AML and 44 with t(8;21) Disclosed Different Frequencies but No Impact on Prognosis
Authors: Annette Fasan, Tamara Alpermann, Vera Grossmann, Christiane Eder, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2011)
Neoadjuvant cisplatin/gemcitabine (CG) chemotherapy for muscle-invasive transitional cell carcinoma of the bladder (TCCB): A single-institution experience.
Authors: Scott A. North, Faraj El-Gehani, Peter Venner
Journal: Journal of Clinical Oncology (2012)

304 Background: Despite evidence of a survival advantage for neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy (RC) for muscle-invasive TCCB, many patients are not treated. While many Canadian centers use CG chemotherapy in this setting, there is little data on pathologic response rate, often considered an important predictor of long term outcome. This retrospective study was undertaken to determine the use of neoadjuvant treatment prior to RC at our institution and assess pathologic response rates at time of RC for patients receiving neoadjuvant CG. Methods: A retrospective chart review was performed on all patients undergoing RC between January 1, 2007 and June 30, 2011 in Edmonton, Alberta, Canada. Data were collected on patient demographics, pre-treatment clinical stage information, type and amount of chemotherapy administered, and pathologic data from RC specimens. Results: A total of 251 RC were performed during the study period. Eighty-three RC were performed for non-muscle invasive TCC: 15 non-malignant causes, 27 refractory superficial TCC, 41 non-TCC malignant histology. A total of 168 RC were performed for T2-T4 TCC. Median age at diagnosis was 68 years. Ninety-two (55%) patients received neoadjuvant CG. Seventy-five (45%) patients went straight to RC. Reasons for neoadjuvant GC not being given include: medical contraindication in 43 patients (56%), patient refusal in 9 patients (12%) and lack of referral to Medical Oncologist in 24 patients (32%). Of a possible 116 patients who would have been eligible to receive neoadjuvant chemotherapy, 92/116 (79%) were treated. Of the 92 patients receiving chemotherapy prior to RC, 19 (21%) of the surgical specimens were pathologically free of cancer (pT0) at the time of surgery and 18 (20%) had only superficial disease remaining. By contrast, only three (4%) of the 75 patients who went to immediate RC achieved pT0 status and 5 (7%) had remaining superficial disease. Conclusions: The use of neoadjuvant chemotherapy prior to RC at our institution is higher than quoted in published literature. The use of neoadjuvant GC improves the chances of eliminating residual cancer in the RC specimen.
Gemtuzumab Ozogamicin (Mylotarg®) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).
Authors: Xavier Thomas, Quoc-Hung Le, Emmanuelle Tavernier, Samira Mahmoudi, Youcef Chelghoum, Franck Nicolini, Anne Thiebaut, Jacques Troncy, Daniela Revesz, Mohamed Elhamri, Mauricette Michallet
Journal: Blood (2005)
Interest of axillary lymph node dissection in the case of micrometastatic invasion of the sentinel lymph node: Evaluation of three predicting models of risk of nonsentinel lymph node involvement.
Authors: M. Orsoni, J. Clerc, F. Golfier, D. Raudrant, j. Krauth
Journal: Journal of Clinical Oncology (2011)

e11568 Background: To evaluate three predicting risk models of non sentinel lymph node (NSLN) involvement in case of micrometastatic sentinel node (SLN) involvement for breast cancer. Methods: This retrospective study included 72 successive patients with a micrometastatic SLN involvement who had surgery between March 1996 and October 2007. All patients had an immediately or delayed axillary lymph node dissection (ALND). The MSKCC nomogram, the Stanford nomogram and the Tenon score were applied to our population in order to calculate the probability of NSLN involvement. Statistical analysis with establishment of a ROC curve was applied to each model. Results: Concerning the MSKCC nomogram, w ith a threshold value of 10%, sensitivity was 50%, specificity was 70%, and negative predictive value (NPV) was 89%. The area under the ROC curve (AUC) was 0.6 (significant). ALND was avoided in 49 patients (68%) but it failed to detect 5 out of 10 (50%) patients with NSLN involvement. When using a threshold of 7%, the AUC was 0.69 with a sensitivity of 90% and a NPV of 97%. It avoided 31 out of 72 ALND (43%) while having only 3% chance of leaving metastasis when abstaining from ALND. Concerning the Tenon score, using a threshold of 3.5, the sensitivity lowered to 50% while the specificity was 72% and the AUC 0.62. It was not clinically applicable because 8 out of 10 patients (80%) with NSLN involved were spared from a necessary ALND. Concerning the Stanford nomogram, our results were not interpretable because the AUC was not significant. Conclusions: None of these three models was sufficiently reliable to be used in the daily practice. The MSKCC nomogram showed the most encouraging results especially for a threshold of 7% which is not validated in the literature. Completion axillary dissection should be performed as a standard of management in case of micrometastatic SLN involvement until more available data.